Political manoeuvres by the US Democratic Party could delay passage of the much-anticipated crypto market structure bill (CLARITY Act) until 2027, investment bankPolitical manoeuvres by the US Democratic Party could delay passage of the much-anticipated crypto market structure bill (CLARITY Act) until 2027, investment bank

TD Cowen Warns Midterms Could Stall Crypto Market Structure Push

2026/01/07 13:56
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • US Democrats could block the crypto market structure bill in the Senate until after the midterm elections in November, when the party has a strong chance of regaining control of the House, according to investment bank TD Cowen.
  • The bank said the bill may not pass into law until 2027 and its full implementation could be delayed until 2029.

Political manoeuvres by the US Democratic Party could delay passage of the much-anticipated crypto market structure bill (CLARITY Act) until 2027, investment bank TD Cowen said in a Monday note.

Achieving bipartisan consensus and getting the bill passed before the US Midterm elections in November 2026 could be a tall order, TD Cowen warned. The financial services firm had said in late 2025 that Senate Democrats “are not interested in moving quickly.”

This week the bank’s research arm, led by Jaret Seiberg, reiterated that the Democrats’ belief in their chances to regain control of the House in November could stall progress. TD Cowen said the legislation’s full implementation could stretch out to 2029. 

It’s currently a toss-up for which party is best-placed to wrest control of the House. However, low approval ratings for President Donald Trump and recent Democratic victories, such as the election of Zohran Mamdani in New York, bode well for the Democrats’ prospects.

Election outcomes are always uncertain, which is why Democrats may cut a deal.

Jaret Seilberg, TD Cowen

“That could happen quickly, as staff have been working on the technical language for months,” Seiberg wrote. 

Related: Trump Family Nets $1.3B Boost from Bitcoin Ventures and DeFi Gains

A key sticking point for Dems is the inclusion of provisions designed to reduce conflicts of interest arising from government officials, including President Donald Trump and his family, profiting from crypto projects. That would be a “nonstarter” for Trump, according to Seiberg. 

Time favors enactment as the problems disappear if the bill passes in 2027 and takes effect in 2029. Crypto would need to accept that the presidential election could impact the final rules, and Democrats would need to accept that the conflict provision will not apply to Trump.

Jaret Seilberg, TD Cowen

Revision Process Already Underway in 2026

While the CLARITY Act was passed by the US House of Representatives in mid-2025, ongoing debate over the bill’s inclusions meant it didn’t proceed to a vote in the Senate. In the Senate, the bill is named the Responsible Financial Innovation Act. 

Related: Goldman Sachs Sees Regulatory Shift Fuelling Next Phase of Crypto Adoption

Senators from both parties met again on Tuesday, 6 January, to relaunch talks over the market structure bill. While no official announcement has been made on the next step in the negotiations, Republican Senator John Kennedy reportedly told a Punchbowl News journalist that a bill markup (a session where senators debate amendments) would happen “next week”.

“My understanding is that the chairman is gonna have a vote, come hell or high water, on Thursday for the next week,” Kennedy reportedly said.

The post TD Cowen Warns Midterms Could Stall Crypto Market Structure Push appeared first on Crypto News Australia.

Market Opportunity
EPNS Logo
EPNS Price(PUSH)
$0.012023
$0.012023$0.012023
+1.11%
USD
EPNS (PUSH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09